#2026

3 articles tagged #2026.

#2026 3#503a 1#503b 2#FDA 1#alternatives 1#ban 1#before-and-after 1#beginners 2#brand-name 3#bridge-program 2#cagrilintide 1#cagrisema 1#comparison 2#compounded 7#compounded-semaglutide 1#compounded-tirzepatide 1#compounding-ban 1#copay 1#cost 12#countdown 1#coupon 1#coverage 1#diabetes 1#diet 1#dosage 1#eli-lilly 3#enforcement 1#enrollment 1#fact-check 1#fda 3#fda-approval 1#flat-rate 1#foundayo 7#framework 1#glp-1-patches 1#glucose-monitors 1#guide 1#hhs 1#hims 1#how-to-get 1#injectable 6#injection 1#insurance 11#ivy-rx 1#ivyrx 1#legality 1#liraglutide 1#medicaid 1#medicare 6#mounjaro 5#news 3#novo-nordisk 2#oral-glp1 6#oral-semaglutide 1#orforglipron 4#ozempic 5#pill 1#pipeline 1#policy 1#prior-authorization 2#regulation 2#results 1#rfk 1#ro 1#safety 3#savings-card 1#schedule 1#semaglutide 17#shortage 1#side-effects 9#supplements 1#surmount 2#surmount-5 1#telehealth-enforcement 1#telehealth-review 1#timeline 1#tirzepatide 17#warning-letters 1#wegovy 15#wegovy-hd 1#wegovy-pill 3#weight-loss 25#without-insurance 1#zepbound 17
Editorial lifestyle photograph illustrating a morning wellness routine with a glass of water on a clean kitchen counter
GuideComparisonsJune 22, 2026• 10 min read

Oral GLP-1 Pills for Weight Loss (2026): Foundayo, Oral Semaglutide (Wegovy) & All Options

As of 2026, two FDA-approved oral GLP-1 pills exist for weight loss: Foundayo (orforglipron, 12.4% weight loss, $149/mo self-pay via LillyDirect, no fasting needed, approved April 1) and the Wegovy pill (semaglutide 25mg, 16.6% weight loss, $1,349/mo list price, requires 30-min fast before dosing, approved December 2025). Rybelsus is oral semaglutide but approved for type 2 diabetes only — not weight loss.

Editorial lifestyle photograph illustrating a review of IvyRx GLP-1 telehealth service
AnalysisComparisonsMay 12, 2026• 9 min read

IvyRx GLP-1 Review 2026: Flat-Rate Compounded Semaglutide & Tirzepatide at $175–$297/mo

IvyRx offers compounded semaglutide from $175/month and tirzepatide from $275/month with a rare flat-rate model — your price never increases as your dose goes up. We reviewed their pricing, clinical oversight, and transparency. Key finding: the flat-rate pricing is genuinely valuable, but IvyRx doesn't publicly disclose a named medical director or their compounding pharmacy partners, which are meaningful gaps for patients who want to verify clinical quality.

Editorial lifestyle photograph of official documents on an oak desk illustrating a regulatory proposal
NewsNews & PipelineMay 8, 2026• 7 min read

FDA Proposes Permanent 503B Compounding Ban for Semaglutide, Tirzepatide & Liraglutide

Verified May 8, 2026: On April 30, FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulk list — forever, not just during shortage enforcement. Public comment closes June 29, 2026. If finalized, no 503B pharmacy could bulk-compound these GLP-1 drugs in the future, even if a new shortage is declared. 503A patient-specific compounding under medical-necessity remains unaffected.

Featured Partners

Four affiliate partners we feature — we may earn a commission.

TrimRx

7.8/10
$179/mo·Brand & Compounded
Visit TrimRxReview

Gala

7.2/10
$149/mo·Brand & Compounded
Visit GalaReview

SkinnyRx

7.3/10
$199/mo·Compounded
Visit SkinnyRxReview

Embody

7.3/10
$299/mo·Compounded
Visit EmbodyReview

Affiliate links — we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics — not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at glp1picks.com/best.

Top PickTrimRx · $179/moGet →